加载中
NASDAQHealthcareBiotechnology
最新数据
US$1.77
−US$0.13 · -6.84%
Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment. It aims to treat both ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition. Processa's portfolio also features PCS12852, a unique selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. This compound is currently in Phase 2A clinical trials for its potential application in managing gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia. Furthermore, the firm is advancing PCS3117, a cytosine analog, which has reached Phase 2B clinical trials for its use in pancreatic cancer and non-small cell lung cancer. Another candidate, PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase, is progressing through Phase 1B clinical trials for metastatic colorectal and breast cancers. In addition, Processa is developing PCS11T, an analog derived from the drugs SN38 and irinotecan, intended for the treatment of diverse cancer types. The company was founded in 2011 and maintains its corporate headquarters in Hanover, Maryland.
收盘时
US$1.77
−US$0.13 · -6.84%
盘后
US$1.74
−US$0.03 · -1.69%
10月13日 19:53 ET
盘中时间采用ET。市场数据可能有所延迟。
Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment. It aims to treat both ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition. Processa's portfolio also features PCS12852, a unique selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. This compound is currently in Phase 2A clinical trials for its potential application in managing gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia. Furthermore, the firm is advancing PCS3117, a cytosine analog, which has reached Phase 2B clinical trials for its use in pancreatic cancer and non-small cell lung cancer. Another candidate, PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase, is progressing through Phase 1B clinical trials for metastatic colorectal and breast cancers. In addition, Processa is developing PCS11T, an analog derived from the drugs SN38 and irinotecan, intended for the treatment of diverse cancer types. The company was founded in 2011 and maintains its corporate headquarters in Hanover, Maryland.
日内区间
当前US$1.77
52周区间
当前US$1.77
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
43
合理估值
情绪
54
多空交织
风险
71
高风险
动量
25
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment. It aims to treat both ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition. Processa's portfolio also features PCS12852, a unique selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. This compound is currently in Phase 2A clinical trials for its potential application in managing gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia. Furthermore, the firm is advancing PCS3117, a cytosine analog, which has reached Phase 2B clinical trials for its use in pancreatic cancer and non-small cell lung cancer. Another candidate, PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase, is progressing through Phase 1B clinical trials for metastatic colorectal and breast cancers. In addition, Processa is developing PCS11T, an analog derived from the drugs SN38 and irinotecan, intended for the treatment of diverse cancer types. The company was founded in 2011 and maintains its corporate headquarters in Hanover, Maryland.
日内区间
当前US$1.77
52周区间
当前US$1.77
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | — | — | 87.4万 USD | — |
| 毛利 | — | — | — | −87.4万 USD | — |
| 研究与开发 | 781.03万 USD | 726.91万 USD | 579.95万 USD | 1070.57万 USD | 687.8万 USD |
| 销售、一般及管理费用 | 617.82万 USD | 478.21万 USD | 565.75万 USD | 867.75万 USD | 468.89万 USD |
| 营业费用 | 1398.85万 USD | 1205.12万 USD | 1145.71万 USD | 1938.33万 USD | 1213.35万 USD |
| 利息收入 | 10.95万 USD | 20.11万 USD | 33.55万 USD | 10.12万 USD | 1.2万 USD |
| 利息支出 | — | — | — | — | 362 USD |
| 折旧和摊销 | 1204 USD | 782 USD | 222 USD | 78.85万 USD | 79.1万 USD |
| 营业利润 | −1398.85万 USD | −1205.12万 USD | −1145.71万 USD | −2025.73万 USD | −1213.35万 USD |
| 净利润 | −1356.38万 USD | −1185.01万 USD | −1112.15万 USD | −2742.42万 USD | −1142.75万 USD |
公司数据更新于 2026年10月14日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$225
上涨空间 12611.86%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年12月17日 | 1:25 | — | — |
股票拆分 | 2024年1月22日 | 1:20 | — | — |
股票拆分 | 2019年12月23日 | 1:7 | — | — |
股票拆分 | 2017年12月8日 | 1:7 | — | — |
已生效 2025年12月17日
1:25
已生效 2024年1月22日
1:20
已生效 2019年12月23日
1:7
已生效 2017年12月8日
1:7
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
